Logo
x

Search

Subscribe Now

REGENXBIO

REGENXBIO Reports the Clinical Trial Results for RGX-121 to Treat Mucopolysaccharidosis Type II (MPS II)

REGENXBIO Reports the Clinical Trial Results for RGX-121 to Treat Mucopolysaccharidosis Type II (MPS II)

  • February 8, 2024
REGENXBIO’s RGX-121 Receives the US FDA’s RMAT Designation for the Treatment of Hunter Syndrome

REGENXBIO’s RGX-121 Receives the US FDA’s RMAT Designation for the Treatment of Hunter Syndrome

  • May 24, 2023
REGENXBIO Reports Interim Results of RGX-314 in the P-II Bridging Study for Wet Age-Related Macular Degeneration

REGENXBIO Reports Interim Results of RGX-314 in the P-II Bridging Study for Wet Age-Related Macular Degeneration

  • February 13, 2023
REGENXBIO Initiates P-I/II Trial of RGX-202 for the Treatment of Duchenne Muscular Dystrophy

REGENXBIO Initiates P-I/II Trial of RGX-202 for the Treatment of Duchenne Muscular Dystrophy

  • January 24, 2023
REGENXBIO Presents Interim P-II (ALTITUDE) Trial Results of RGX-314 for Diabetic Retinopathy Using Suprachoroidal Delivery at 55th Annual Retina Society Meeting

REGENXBIO Presents Interim P-II (ALTITUDE) Trial Results of RGX-314 for Diabetic Retinopathy Using Suprachoroidal Delivery at 55th...

  • November 3, 2022
REGENXBIO Reports Interim P-II (AAVIATE) and P-I/IIa Long-term Follow-up Study of RGX-314 for Wet AMD

REGENXBIO Reports Interim P-II (AAVIATE) and P-I/IIa Long-term Follow-up Study of RGX-314 for Wet AMD

  • October 4, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.